

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



FOR IMMEDIATE RELEASE

Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.

- *New website highlights the efficacy and safety profile for each product, while also educating healthcare providers and patients about our intent to mitigate risks associated with improper medication manipulation*
- *Sun Pharma's alternative-formulation products are designed for the up to 40% of US adults who cannot or will not swallow solid medication forms and to avoid medication errors*

Mumbai, India, and Princeton, NJ, February 25, 2021 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced the U.S. launch of the website for its long-term care (LTC) division, www.sunltc.com. The new website presents Sun Pharma's LTC portfolio of alternative formulation products and underscores Sun Pharma's commitment to meeting the needs of the up to 40% of American adults who cannot or will not swallow solid medication forms.¹

Sun Pharma's LTC portfolio includes the first and only U.S. Food and Drug Administration (FDA)-approved extended-release sprinkle formulation of metoprolol succinate; the first and only FDA-approved sprinkle formulation of delayed-release duloxetine; and the first and only approved sprinkle formulation of rosuvastatin, Ezallor Sprinkle™ (rosuvastatin) immediate-release capsules. The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.

"Through this website, Sun Pharma aims to call attention to the broad need for our three alternative sprinkle formulations of widely prescribed medications, which are designed for those who cannot or will not swallow solid medication forms," said Mark Hagler, Senior Vice President and Head of Ophthalmics, Oncology and LTC at Sun Pharma. "These products are also being prescribed outside of LTC facilities, suggesting a broader need for alternative administration options of commonly used therapies that cannot be crushed. Our new website highlights the efficacy and safety profile for each product, while also educating healthcare providers and patients about our intent to mitigate risks associated with improper medication manipulation."

One of the most common errors is crushing tablets that appear on the "Do Not Crush" list, a manipulation that can alter the pharmacokinetic properties, therapeutic efficacy, and safety profile of the medication.^{2,3}

For more information about the Sun Pharma portfolio of LTC products, please visit www.sunltc.com.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live.

Disclaimer

Statements in this Document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the interpretations of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

References:

1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. *Size, Shape, and Other Physical Attributes of Generic Tablets*. www.fda.gov/media/87344/download. Published June 2015. Accessed January 6, 2020.
2. Thong MW, Manrique YJ, Steadman KJ. Drug loss while crushing tablets: comparison of 24 tablet crushing devices. *PLoS ONE*. 2018;13(3):e0193683.
3. Institute for Safe Medication Practices. List of oral dosage forms that should not be crushed. November 1, 2018.

Contacts:

Investors:

Nimish Desai
Tel +91 22 4324 4324, Xtn 2778
Tel Direct +91 22 4324 2778
Mobile +91-98203 30182
E mail nimish.desai@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com

US Media:

Vinita Alexander
Tel Direct +1 609-720-8197
Email vinita.alexander@sunpharma.com

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



Reba Auslander

Tel Direct +917-836-9308

Email reba@raliancecommunications.com